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Abstract
Background: Dental caries in the expanding elderly, predominantly-dentate population is an emerging public
health concern. Elderly individuals with heavily restored dentitions represent a clinical challenge and significant
financial burden for healthcare systems, especially when their physical and cognitive abilities are in decline.
Prescription of higher concentration fluoride toothpaste to prevent caries in older populations is expanding in the
UK, significantly increasing costs for the National Health Services (NHS) but the effectiveness and cost benefit of this
intervention are uncertain. The Reflect trial will evaluate the effectiveness and cost benefit of General Dental
Practitioner (GDP) prescribing of 5000 ppm fluoride toothpaste and usual care compared to usual care alone in
individuals 50 years and over with high-risk of caries.
Methods/design: A pragmatic, open-label, randomised controlled trial involving adults aged 50 years and above
attending NHS dental practices identified by their dentist as having high risk of dental caries. Participants will be
randomised to prescription of 5000 ppm fluoride toothpaste (frequency, amount and duration decided by GDP)
and usual care only. 1200 participants will be recruited from approximately 60 dental practices in England, Scotland
and Northern Ireland and followed up for 3 years. The primary outcome will be the proportion of participants
receiving any dental treatment due to caries. Secondary outcomes will include coronal and root caries increments
measured by independent, blinded examiners, patient reported quality of life measures, and economic outcomes;
NHS and patient perspective costs, willingness to pay, net benefit (analysed over the trial follow-up period and
modelled lifetime horizon). A parallel qualitative study will investigate GDPs’ practises of and beliefs about
prescribing the toothpaste and patients’ beliefs and experiences of the toothpaste and perceived impacts on their
oral health-related behaviours.
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Discussion: The Reflect trial will provide valuable information to patients, policy makers and clinicians on the costs
and benefits of an expensive, but evidence-deficient caries prevention intervention delivered to older adults in
general dental practice.
Trial registration: ISRCTN: 2017-002402-13 registered 02/06/2017, first participant recruited 03/05/2018.
Ethics Reference No: 17/NE/0329/233335.
Funding Body: Health Technology Assessment funding stream of National Institute for Health Research.
Funder number: HTA project 16/23/01.
Trial Sponsor: Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL.
The Trial was prospectively registered.
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Background
The UK has an ageing population. The number of
people of State Pension Age and over is projected to in-
crease by 32.7% from 12.4 million in mid-2014, to 16.5
million by mid-2039. Likewise the number of people
aged 75 and over is projected to rise by 89.3%, to 9.9
million, over the same period [1]. Whilst an increase in
life expectancy should be celebrated, attention needs to
be given to the complex health needs, including oral
health needs, of the growing population of older people.
Dental caries is preventable, yet it is the most common
disease worldwide. In high-risk older populations it is an
important public health issue, as the number of older
people who retain their natural teeth is growing rapidly.
In England in 2009, 6% of the adult population were
edentulous, compared to 28% in 1978 [2]. Dentate older
adults tend to have extensively restored teeth [2], mainly
due to them having grown-up prior to the widespread
use of fluoride toothpaste (introduced in the 1970’s). For
these older adults, the risk of developing dental caries
increases due to the presence of restorations and pros-
theses (bridges or dentures) that increase plaque reten-
tion, dry mouth (often as a result of polypharmacy),
exposed root surfaces and a cariogenic diet. The oral
health of these individuals will decline as their physical
and cognitive abilities deteriorate, resulting in a growing
population health problem with significant financial re-
percussions for the NHS; so prevention of caries is im-
portant [3].
Recent National Institute for Health and Care Excel-
lence (NICE) guidance recognised the impact poor oral
health can have on older individuals’ ability to eat, speak
and socialize [4]. This guidance focused on those living
in care homes (either nursing or residential), however,
the majority of the 11 million adults in the UK, aged 65
years or over, live in their own homes, with less than 4%
(approximately 414,000) living in some form of care
home [4]. It is therefore important to establish a strong
evidence base for the management of the oral health
needs of older people across all residential settings. In the
four countries of the UK dental policy on reforming NHS
dental contracts places an emphasis on General Dental
Practitioners (GDPs) providing effective caries prevention
[5] and they have a central role in maintaining the oral
health of the older population. The significant reductions
in dental caries prevalence and severity over the last 40
years have primarily been attributed to fluoride toothpaste
[6]. More recently high concentration, prescription-only
fluoride toothpaste has been used increasingly in the man-
agement of patients with high risk of caries [7].
The current evidence to support prescription of high
concentration fluoride toothpaste (specifically 5000 ppm
(ppm) toothpaste) to prevent caries is weak [8–10]. A
Cochrane review of different doses of fluoride toothpaste
did not include any randomised controlled trials of 5000
ppm fluoride, however the review did find a
dose-response relationship between the concentration of
fluoride in toothpaste and caries prevention, with greater
caries prevention for higher doses of fluoride [10]. This
review is currently being updated to include adults: no
trials on the prevention of coronal caries through the
use of 5000 ppm toothpaste have been identified. A
more recent review of high fluoride concentration
toothpastes included four studies (randomised and
non-randomised) with 5000 ppm fluoride toothpaste
[11]. None of these studies meet the inclusion criteria
for the Cochrane review and all have significant design
and methodological limitations. However, despite the
weak evidence base, GDPs in England are advised by na-
tional guidance published by Public Health England to
prescribe high concentration 2800/5000 ppm fluoride
toothpaste for older adults with active caries or those at
risk of developing caries [12]. The prescription of this
technology is expanding; in England in 2014 1.3 million
items were prescribed at a cost of £17 million [13], a
12.2% increase from the previous year and similar in-
creases are evident in Scotland [14]. We have little un-
derstanding of how this growing NHS investment
benefits patients, or if it can play a useful role in tackling
an emerging public health problem. There is a need for
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clear, evidence-based guidance on the prescribing of
high concentration fluoride toothpaste in older adults
for caries prevention.
Methods/design
Trial aims and objectives
Aim
To evaluate the effectiveness and cost benefit of GDP
prescribing of 5000 ppm fluoride toothpaste and usual
care compared to with usual care alone in individuals
50 years and over with high-risk of caries.
Primary objective
 To compare the effect of prescribing 5000 ppm
fluoride toothpaste and usual care with usual care
alone on treatment for caries, including coronal/root
restorations, endodontics or extractions
 To compare the costs and benefits, within a net
benefit framework of prescribing 5000 ppm fluoride
toothpaste with usual care
Secondary objectives will evaluate the effect of pre-
scribing 5000 ppm fluoride toothpaste on caries (mean
Decayed Missing Filled Surfaces [DMFS]) increment,
progression of early caries lesions, bleeding on probing,
quality of life (generic and condition specific), costs to
the NHS and to individuals and society, oral health be-
haviour and episodes of pain. In addition, we will ex-
plore the attitudes of clinicians and patients to the
prescribing and use of high fluoride toothpaste.
Study design
A two arm, parallel group, pragmatic, open label Rando-
mised Controlled Trial (RCT) comparing the clinical ef-
fectiveness and cost benefit of GDP prescribed high
concentration fluoride toothpaste and usual care com-
pared to usual care alone in preventing and treating dental
caries in older patients. The Medicines and Healthcare
products Regulatory Agency (MHRA) has ruled that the
trial should be categorised as a Type A trial, as described
in Risk proportionate approaches in clinical trials [15].
A flow diagram for the trial is provided in Fig. 1. Fol-
low up will last 3 years and will be conducted in multiple
sites (approximately 60 General Dental Practices) located
in England, Scotland and Northern Ireland.
In parallel with the trial we will undertake a qualitative
project to understand GDPs’ practises and beliefs about
prescribing 5000 ppm fluoride toothpaste and patients’
beliefs and experience of being prescribed 5000 ppm
fluoride toothpaste and perceived impacts on their oral
health related behaviours. Furthermore, this element will
also provide GDPs’ and patients’ feedback concerning re-
cruitment to inform our recruitment strategy. The
qualitative protocol is included as Additional file 1:
Appendix 1.
Ethical considerations
Favourable ethical opinion for the REFLECT study was
confirmed by the North East - Newcastle & North Tyne-
side 1 Research Ethics Committee on 17th November
2017 (REC reference number 17/NE/0329). The MHRA
had no objection to the trial being classified as Type A
under the notification scheme for risk-adapted Clinical
Trials of Investigational Medicinal Products. The trial
will be conducted according to the principles of Good
Clinical Practice provided by Research Governance
Guidelines [16]. Annual progress reports, notification
of End of Trial, and a final report at the conclusion
of the trial will be submitted to REC and to the
MHRA within the timelines defined in the regula-
tions. An independent Trial Steering Group supported
by an independent Data Monitoring Group will over-
see the conduct of the trial.
Participants are required to provide written informed
consent to participate in the study, the consent form for
the trial is included as Additional file 2: Appendix 2. Po-
tential participants will receive a letter of invitation and
a trial information sheet detailing the process and proce-
dures of the trial and the nature of the intervention to
be tested. Dentists will take informed consent using an
approved consent form within the practices and will ver-
bally reiterate the information contained in the informa-
tion sheet and answer any questions that patients may
have about the trial as part of the informed consent
process. All participants will be given a £25 gift voucher
at the start of the trial and another £25 voucher at the
end in acknowledgment of the time that participation in
the trial will entail and to thank them for their support.
Consent from participants for direct access to data will
also be obtained. The patients’ confidentiality will be
maintained and will not be made publicly available to
the extent permitted by the applicable laws and
regulations.
Study participants
Participants will be identified in multiple sites (ap-
proximately 60 General Dental Practices) located in
England, Scotland and Northern Ireland. Participants
will be NHS dental patients, 50 years of age or older
who are considered by their dentist to be at high risk
of developing caries. Our decision to use the lower
limit of 50 years of age was based on: in the UK high
concentration fluoride toothpaste is currently being
prescribed to individuals between 50 and 60 years
[17]; individuals 50 years and over have grown up in
the absence of widespread use of fluoride toothpaste
and consequently many individuals in this age group
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have heavily restored dentitions, increasing their car-
ies risk [2]; the 2009 Adult Dental Health Survey sug-
gests that those individuals with complex dental
needs are most prevalent in late middle age [3]. In-
cluding a broad age range in the trial provides an op-
portunity to assess the impact of prescribing on
different age groups in this older population.
High-risk individuals will be defined by: a diagnosis of
active caries (into dentine) in the last 12 months which
may/may not have been treated, or any root caries; and/
or other risk factors as determined by their GDP. Partic-
ipants can be living in any residential setting but must
receive their dental care at a general dental practice (pri-
mary care). Participants will be assessed for inclusion by
their GDP according to the trial inclusion and exclusion
criteria.
Inclusion criteria: People who
 are aged 50 years or older
 with a diagnosis of active coronal caries (into
dentine) in the last 12 months which may\may not
have been treated, or any root caries; and\or other
risk factors as determined by their GDP.
 receive their dental care in part or fully as an NHS
patient
 are living in any residential setting, and
 for whom their GDP decides prescription of high
concentration fluoride toothpaste is appropriate for
the patient
Exclusion criteria: People who:
 are currently prescribed (by GDP or GP) high
concentration fluoride toothpaste (for GDPs
prescription must have been issued at last
examination visit)
 hypersensitivity for Sodium Fluoride and\or other
ingredients used in 5000 ppm toothpaste
*based on 50% consent rate of the IQuaD trial
** based on 25% attrition rate over 3 years 
Invited for screening for eligibility
(n= 2348)
Lost to follow-up (n=147; 25.0%)**
Analysed (n= 440; 75.0%)
Excluded from analysis (n= 0)
Lost to follow-up (n=147; 25.0%)**
Allocated to intervention group (n=587) Allocated to control group (n= 587)
Analysed (n= 440; 75.0%)
Excluded from analysis (n= 0)
Allocation
Analysis
Follow-Up
(36 Months)
Enrolment
Randomization
n = 1174
Excluded
(n= 1174) *
Fig. 1 Trial Flow Diagram
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 are living in the same household as someone already
recruited to Reflect, or someone who is routinely
using a high concentration fluoride toothpaste
 are unable to provide informed consent
Trial intervention
The trial intervention is prescription of 5000 ppm fluor-
ide toothpaste, used as prescribed by the participant’s
GDP and informed by national guidance [12]. The inter-
vention is designed to reflect current dental practise and
therefore the frequency of prescription, the number of
tubes of toothpaste per prescription and the duration of
the regimen will be determined by the patient’s GDPs
after assessing each patient’s risk. We have restricted the
intervention to 5000 ppm fluoride toothpaste, as NHS
prescribing data shows that 5000 ppm is more com-
monly prescribed than the 2800 ppm alternative [17].
Current guidance recommends that for those adults
with obvious active coronal or root caries dentists
should prescribe high fluoride toothpaste [12]. Our in-
clusion criteria are less restrictive to allow for prescrip-
tion based not just on caries activity, but also based on
other risk factors, as determined by the GDP. This ap-
proach is based on the hypothesis that 5000 ppm fluor-
ide toothpaste can prevent caries in those patients
deemed to be high risk by their dentist, even though
they don’t present with ‘obvious’ caries. For true primary
prevention, the identification of risk factors in advance
of disease is indicated.
The Investigational Medicinal Product (5000 ppm fluor-
ide toothpaste) prescribed will not be specified by manu-
facturer or individual product. A clinical trials pharmacy
will not be used to dispense the drug. The drug will be
used as prescribed by the participant’s GDP and as indi-
cated by the British National Formulary. Participants will
be expected to collect their prescriptions at a local com-
munity pharmacy as per usual practice. GDPs will provide
instructions to each participant based on their assessment
of risk and how they prescribe the drug.
Compliance will depend on both GDPs’ and partici-
pants’ behaviour, the trial will not seek to ensure a min-
imal level of compliance. Compliance will be assessed to
determine its impact on trial outcomes by recording
GDPs’ self-reported prescribing behaviour frequency and
duration of prescriptions and the number of tubes pre-
scribed, accessing national datasets to identify if partici-
pants’ re-deem prescriptions or receive prescriptions
from other sources and via participants’ (both test and
control groups) self-reported use of toothpaste.
The comparator will be usual care; usually advice given
by the participant’s GDP to buy ‘standard’, off-the-shelf
1350-1500 ppm fluoride toothpaste and use as advised by
their dentist informed by national guidance [12]. Other
recommendations in the national guidance [12] for
self-administered (mouthwash) or professionally-applied
(varnish) fluoride delivery methods could have an impact
on the trial. We will take a pragmatic approach and leave
the decision to use other fluoride delivery systems to the
patients and their dentist, but the use of these interven-
tions will be recorded.
Outcome measures
Primary outcome
The proportion of participants receiving any dental
treatment due to caries; including restorations, endodon-
tics or extraction. Any dental treatment provided and
the reasons for providing treatment (caries, tooth wear
or other e.g. trauma) will be recorded. The primary out-
come (treatment directly due to caries) will be extracted
from the Clinical Report Form (CRF).
Secondary outcomes (clinically assessed)
The clinically assessed secondary outcomes will be mea-
sured in Scottish practices only; Additional file 3: Ap-
pendix 3 provides a sub-protocol for this more intensive
assessment of participants
 Coronal caries increment, including dentist replacement
restorations for caries, at tooth surface (DMFS) level by
independent, trained and calibrated, clinical examiners
at baseline and 3 year (+/− 3months) follow-up. We will
use the ICDAS method [18] to assess caries as it pro-
vides flexibility to analyse and present caries data at dif-
ferent diagnostic thresholds.
 Root caries increment, including dentist replacement
restorations for caries, at tooth surface (DMFRS)
level by independent, clinical examiners at baseline
and 3 year (+/− 3 months) follow-up.
 Early caries lesion progression data, using ICDAS.
 Bleeding on probing (BoP) will also be recorded by
the independent clinical examiners. BoP provides
evidence of long term optimal brushing rather than
transitory measures such as visible plaque scores [19].
Secondary outcomes (patient reported)
 Oral health status using OHIP14, a measure of oral
health-related Quality of Life (QoL), collected at
baseline and annual follow up through patient ad-
ministered questionnaires. The OHIP-14 is the most
common, validated dental quality of life instrument
and has been successfully used in previous HTA tri-
als. It has been found to be sensitive to differences
in oral health and is closely correlated with self-
reported oral health outcomes [20]
 The EQ-5D-5 L profile measure of generic health
status [21, 22], will be collected at baseline and an-
nual follow up through patient questionnaires.
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 Any episode of dental pain (and total number per
participant) during the 3 year follow up period,
severe enough to trigger seeking advice from a
healthcare professional (dentist, GP, community
pharmacist). This will be recorded at scheduled and
unscheduled dental visits by patient questionnaire
included in the CRF.
 Oral health behaviour, including self-reported brush-
ing/other sources of fluoride. Evaluated at baseline
and through annual questionnaires sent by mail to
the home address of participants.
Routine data
 Fulfilment of prescriptions will be measured via
Business Services Authority (BSA), Business Services
Organisation (BSO) and Information Services Division
(ISD) datasets. Adherence to the allocated
intervention (prescription of 5000 ppm) will also be
explored by dentist and participant self-reporting (via
CRF) and in the qualitative interviews with patients
Economic outcomes
 Provision of NHS and privately-funded dental treat-
ments will be collected from the CRF. In addition
we will also collect information on NHS treatment
completed using routinely collected NHS data held
by the ISD, BSA and BSO. Treatment cost data will
be collected for participants from 1 year prior to
randomisation until the end of the trial.
 All remaining resource use data will be collected
using questionnaires provided to participants on
attendance for dental care or mailed to
participants who fail to attend. These will include
the use of other NHS healthcare services (e.g. GP
visits, dental hospital attendances and other
healthcare resource use) directly related to dental
problems as well as data on non-NHS costs (e.g.
time and travel costs, time off work, privately
purchased care, self-purchased dental care
products).
 Collection of EQ-5D-5 L will enable the calculation
of the mean cost per additional QALY as a second-
ary health economic outcome.
 A discrete choice experiment (DCE) with an online
representative sample of the UK general population
(aged 50 and over) will be undertaken to elicit
willingness to pay (WTP) for high fluoride
toothpaste and associated patient relevant outcomes
 Long term economic evaluation with trial results
extrapolated over a life-time horizon using Markov
modelling methods
The methods used to collect the various outcome
measures are summarised in Table 1.
Follow up of participants
Participants will be followed up for a 3-year period. Par-
ticipants will remain in the trial unless they choose to
withdraw consent or if they are unable to continue for
clinical reasons. All changes in status with the exception
of complete withdrawal of consent will mean the partici-
pant is still followed up for all trial outcomes wherever
possible. Participants randomised to 5000 ppm fluoride
toothpaste, who for whatever reason, stop using the trial
medication or participants randomised to routine care
but who purchase or otherwise receive high fluoride
toothpaste will not be considered to have withdrawn
from the trial.
The Sponsor and CI have undertaken an initial risk as-
sessment, which will be periodically reviewed and if ne-
cessary updated as the trial progresses. The Sponsor has
concluded that this is a low risk trial, as the drug is be-
ing prescribed by GDPs as per its licensed indications. It
is topically administered and the known side effects are
rare and minor in nature [23].
Any Serious Adverse Reactions (SARs) will be re-
corded from the time a participant consents to join
the study until the end of their follow up. The local
investigator (GDP) will record in the CRF all directly
observed Adverse Reactions (ARs) and all ARs spon-
taneously reported by participants that have a possible
causal link to the IMP. In addition, each trial partici-
pant will be asked to complete a questionnaire at
each attendance at their dental practice, and one sent
annually to their home, which collects information on
potential ARs and SARs.
The Sponsor and CI will ensure, through the inde-
pendent Trial Steering Committee, that adequate sys-
tems are in place for monitoring the quality of the trial
(compliance with appropriate governance) and appropri-
ate expedited and routine reports, to a level appropriate
to the risk assessment of the trial.
Randomisation
Randomisation will be at patient level. Eligible and con-
senting participants will be randomised to intervention
and control groups using a web-based application,
hosted by the Clinical Trials Unit (CTU) CHaRT
(Centre for Healthcare and Randomised Trials). The
Principal Investigator (PI), or individual at site with dele-
gated authority, will access the web-based system to ran-
domise participants. The randomisation algorithm will
use recruitment site, residential setting (own home/care
home), exemption from dental treatment charges (yes/
no) and age (50–65 years/over 65 years) as minimisation
covariates to allocate treatment to intervention and
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control groups in a 1:1 ratio. A random element will be
incorporated into the randomisation algorithm. Partici-
pants will be informed of their allocated treatment group
following randomisation. The trial statistician and the
study team will be blinded to the allocation during all
analyses by use of a code to identify the two groups. The
key to the code will be held by the CTU.
Blinding of outcome assessment using the primary
outcome will not be possible, as the participant’s dentist
will collect primary outcome data. A more detailed clin-
ical examination undertaken by independent (external to
the trial dental practices) examiners will be used to re-
peat primary outcome measures and collect secondary
outcomes (coronal and root caries increments and
bleeding on probing). This more detailed clinical exam-
ination will take place in Scottish practices only and the
independent examiners will be blind to the allocation.
Source data verification will be undertaken according to
the monitoring plan by:
1. Comparing the primary outcome measures with
outcomes recorded in the clinical examination
(Scotland only)
2. Comparing primary outcome measure in the CRF
treatment provided for caries (coronal and root
surfaces) including restoration, extraction and
endodontics with centralised NHS treatment claims
data for individual patients.
3. Source data verification audits in annual visits of
each practice.
Sample size considerations
The sample size calculation is based on a meaningful ab-
solute target difference of 10% (75% vs 65%) in the pri-
mary outcome measure. This difference is considered to
be both a realistic and important difference from discus-
sion with dentists, PPI groups and from published esti-
mates [6, 7]. The value for the comparator group (75%
of individuals allocated to standard care who have resto-
ration(s) or extraction(s) due to caries during the 36
months of follow up) is based on published data and
Scottish treatment data [24]. For the proposed target dif-
ference, a two-sided 5% significance level, and 90%
power, 440 participants (880 in total) will be required to
provide data for the primary outcome at 36 months.
Based on our previous and current HTA trials, we are
assuming 25% attrition, and so 587 participants per
group are required (1174 in total) in approximately 60
practices (each practice recruiting an average of 20 par-
ticipants). Based on an estimated consent rate of 50%
[data from IQuad [25]], 2348 eligible patients will be in-
vited to participate.
An important secondary outcome within our proposed
trial is caries increment, measured using the number of
Decayed Missing and Filled tooth Surfaces (DMFS).
Using the mean number of Decayed Missing and Filled
tooth Surfaces (DMFS), the caries increments for an
older population in the published literature vary, but
there seems to be consensus around one surface per year
[26]. Given the fact that the standard deviations approxi-
mate the means in terms of caries increment, a
Table 1 Summary of methods used to collect outcome measures
Baseline Elective and non-elective visits to the
dentist over 3 year follow upa
36
months
Annual
Questionnaire
National
Database
Clinical Status (full dental chart) ○ ○ ○
Treatment details
Check ups, restorations, endodontics, extractions (reason for treatment in
CRF and all NHS treatments in national datasets)
Prescription of toothpaste (date and amount prescribed)
Relevant medical history and medication
○ ○ X
Healthcare costs
GDP completed CRF: payment mechanism (NHS/private) and charges levied
Dental treatment received in other settings (patient element of CRF)
NHS costs from national data sets
Non NHS treatment costs in patient element of CRF)
○ ○ ○ X
Detailed independent clinical assessment ICDAS, BoP (Scotland only) ○ ○
EQ-5D-5 L ○ ●
OHIP-14 ○ ●
Pain - seeking professional care because of pain ○ ○
Oral health behaviour ○ ●
Redemption of toothpaste prescriptions ○ ○ ○ X
Adverse reactions ○
adentists should invite participants to attend practice at least once a year
○ Dental Practice – CRF (includes both GDP and participant completed elements)
● Postal Questionnaire
X NHS centralised dental databases
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reduction in caries increment from 3 to 2 surfaces with
the intervention would produce a ~ 30% reduction in
caries increment with the intervention over 3 years. The
numbers needed to adequately power this secondary
outcome are relatively small compared with the primary
outcome measure:
For secondary caries outcomes (Scotland only), group
sample sizes of 200 and 200 achieve 97.5% power to reject
the null hypothesis of equal means when the population
mean difference DMFS increment is μ1 - μ2 = 2–3 = − 1.0
with standard deviations of 2 for group 1 (intervention)
and 3 for group 2 (control), and with a significance level
(alpha) of 0.05 using a two-sided two-sample t-test allow-
ing for unequal variances. Assuming 25% attrition, 267
participants per group are required (534) in total in 28
practices. Based on an estimated consent rate of 50% 1068
eligible patients will be invited to participate.
Statistical analysis
Statistical analysis will be conducted according to a de-
tailed statistical analyses plan (SAP) which will include,
but not be limited to the investigational plan and study
design, listing of outcomes and final analysis including
effectiveness evaluations. The SAP will set out the sum-
mary measures to be reported; methods of analysis,
plans for handling missing data, non-compliance and
withdrawals, the timing and frequency of analyses, and
use of intention to treat analysis.
Demographic (age, sex) and baseline characteristics
(DMFT, DMFS, concomitant illness / treatment,
exempt\not exempt from NHS dental charges) will be
summarised and displayed in tables for all randomised
patients. In addition, mean NHS treatment costs in the
12months prior to recruitment will be included in the
baseline characteristics tables. Frequency counts and
percentages will be used to present categorical data.
Number of patients, mean, mode, median, SD, mini-
mum, maximum and IQR will be used, as appropriate,
to present continuous data.
The primary outcome measure will be analysed using
a generalised linear model with the appropriate link
function adjusting for the minimisation variables (re-
cruitment site, residential setting, exemption (including
partial exemption) from dental treatment charges and
age band). Secondary outcomes will be analysed using
generalised linear models with adjustment for minimisa-
tion and baseline variables when available. Statistical sig-
nificance will be at the 2-sided 5% level with
corresponding confidence intervals derived. Subgroup
analyses on the primary outcome will explore the pos-
sible modification of treatment effect by clinically im-
portant factors; gender, age and NHS dental charges
exemption status. This will be done by including
treatment-by-factor interactions in the model and they
will be classified as exploratory analyses. All analyses will
initially be performed on an intention to treat basis, al-
though we will consider additional analysis groups such
as per-protocol for investigation of adverse events.
Outcome data will not be imputed for the primary
analysis, but score data for participants who have not
returned a scheduled questionnaire will be estimated
using a multiple imputation approach to make use of
partial outcome data. Sensitivity analyses will be con-
ducted to assess the robustness of the treatment effect
estimate to these approaches. Missing items on the
health-related outcome measures will be treated as per
the instructions for that particular measure. There are
no planned interim outcome analyses; all analyses will
occur following completion of trial follow up. Interim
analyses will be performed only if requested by the Inde-
pendent Data Monitoring Committee
Economic evaluation
A full economic evaluation will be conducted as part of
this study:
1. At 3 years of follow up, alongside the primary RCT
outcome measure, and
2. Based on an extrapolation of trial outcomes over a
patient’s life-time, using an appropriate Markov de-
cision analysis model to explore longer term cost-
effectiveness.
The primary economic evaluation will be in the form
of a cost-benefit analysis, reporting net benefit (Willing-
ness To Pay (WTP) - cost), with WTP elicited using a
Discrete Choice Experiment (DCE). We have chosen a
cost-benefit analysis (CBA), as opposed to a traditional
analysis of cost per generic EQ-5D QALY as the primary
economic outcome measure because of concerns that
generic QALYs are not sufficiently sensitive to capture
the processes and outcomes of dental treatments. The
CBA is therefore the outcome of most interest in terms
of investigating value for money (efficiency) of prescrip-
tion of high concentration fluoride toothpaste. In
addition to the primary health economic analysis, two
further analyses will be undertaken as secondary eco-
nomic outcomes to inform various stakeholders:
 NHS decision makers, such as NICE may be
interested in the cost of achieving gains in quality
adjusted life years (QALYs) and therefore
recommend the conduct of a cost per QALY
analysis for technology appraisal. In order to comply
with these recommendations, we will include the
generic EQ-5D-5L health profile measure at baseline
and each follow up time point in the trial. This will
enable the calculation and presentation of the mean
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cost per additional QALY as a secondary health eco-
nomic outcome.
 Dental practitioners may be interested in the cost of
achieving various specific clinical outcomes. We will
therefore complete a cost-effectiveness analysis,
based on the primary clinical outcome measure for
the trial, reporting cost per episode of dental treat-
ment avoided (i.e. the cost per filling or extraction
avoided). A further secondary analysis will present
cost per DMFS avoided.
Estimation of costs
Costs will be estimated from both an NHS and patient
perspective. NHS costs of providing the high fluoride
toothpaste intervention will be based on the costs of dis-
pensed prescriptions verified by BSA, BSO & ISD in
England, Northern Ireland and Scotland respectively.
Methods for the collection of resource use data for cost
estimation over the trial follow up are summarised in
Table 1. All resource use data will be costed at the pa-
tient level, using region specific tariffs, and aggregate
costs applied across these three settings, with sensitivity
analyses presenting data for each setting separately.
Data on costs for each area of service use will be
summed to provide a mean cost per patient participant
(from both an NHS and patient perspective). Incremen-
tal costs per patient for high dose fluoride toothpaste vs
usual care will be estimated using generalised linear
models with appropriate distributions for cost data and
adjustment for baseline covariates, such as gender and
age. The costing analysis will include a statement on
budget impact of alternative policy approaches.
Cost-Benefit Analysis – willingness to pay (WTP)
Whilst health based outcomes are of importance for fun-
ders of dental care, there is a growing interest in wider
measures of value, which go beyond traditional QALY
approaches and offer a more holistic and sensitive meas-
ure of value. It is crucially important for adherence, and
hence real-world cost-effectiveness, that any public
health intervention is not only valued in terms of health
outcomes within a clinical trial, but also has wider gen-
eralisability to the consumers of the intervention. We
will therefore conduct a cost-benefit analysis (CBA)
reporting benefits in terms of WTP to obtain a more
holistic measure of value. WTP will be obtained from a
discrete choice experiment (DCE) [27], conducted with a
nationally representative sample of the general popula-
tion (aged 50 and over), to explicitly value the provision
of high fluoride toothpaste, together with a range of
plausible outcomes from the trial (e.g. avoidance of car-
ies progression). The DCE will explicitly value the high
fluoride toothpaste intervention, together with associ-
ated health outcomes and other important attributes.
The DCE will include a cost attribute. By including
this attribute, the willingness to pay (WTP) for a change
in the level of any other attribute will be estimated. Esti-
mates of WTP derived from the DCE will be combined
with the intervention (provided or not) and clinical out-
come data from the trial to report net benefit [mean
WTP – mean cost [28]] for high fluoride toothpaste
compared to standard care. If benefits are greater than
the costs, then high fluoride toothpaste would be
deemed an efficient use of resources.
Results will be presented on a cost-benefit plane, illus-
trating the probability that the intervention is associated
with positive or negative net benefit. A comprehensive
set of sensitivity analyses will be undertaken to explore
uncertainty in our conclusions. These will include as-
sumptions surrounding missing data, the estimation of
costs and the effect of different payment / co-payment
structures on the cost-benefit results.
Decision modelling
The “within trial” economic analyses will assess and re-
port on the costs and outcomes of high fluoride vs.
standard treatment up to 3 years post-randomisation.
However, the true economic value of an intervention de-
pends on the long-term implications of that interven-
tion. We will develop a de novo Markov decision
analysis model, to extrapolate the trial outcomes over a
longer, life-time horizon [29]. Results will be reported
using a cost-effectiveness framework and estimates of
WTP from the DCE will be used to explore results using
a similar cost-benefit framework to that used for the pri-
mary trial based economic analysis. The final model
structure and health state definition (e.g. caries progres-
sion, new caries, and tooth loss) will be developed in
conjunction with dental experts. National cohort data-
sets, such as the adult dental health survey, and other
longitudinal studies will be used as a source of baseline
transition probabilities. Sensitivity analysis will use the
data from the control (standard care) arm of the trial.
Where possible, survival analysis methods will be used
to assess the time to transition between health states in
each of the study arms, with survival curves fitted over
an extended time frame (patient’s life time). Data from
cohort studies and literature reviews will be used where
necessary to supplement extrapolation models to deter-
mine long run caries progression.
Cost data for health states beyond trial follow up will
be sourced from the trial data and routine data sources
(ISD/BSA/BSO) for appropriate treatment in the re-
spective model health states. To inform a life-time
cost-benefit analysis, estimates of WTP will be sourced
directly from the DCE conducted alongside the trial for
specific health states (e.g. WTP to avoid caries progres-
sion, new caries or tooth loss). The model will be
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developed at an early stage in the study to ensure all
relevant data to populate the model are collected within
the trial. All modelling assumptions will be extensively
tested using sensitivity analyses and the model will be
fully probabilistic. Key gaps in the evidence base will be
identified and their potential impact on cost-
effectiveness explored. Results will be presented using
standard economic evaluation approaches to illustrate
uncertainty. Threshold analyses will be conducted to in-
dicate the values required for key model parameters to
change economic evaluation results. Patients will be
consented to obtain longer-term data linkage to routine
records, which can then be used for future validation of
the extrapolation assumptions.
Research governance, data protection and
sponsorship
The trial will be run under the auspices of CHaRT based
at HSRU, University of Aberdeen. This will aid compli-
ance with Research Governance, and provide centralised
trial administration, database support and economic and
statistical analyses. CHaRT is a registered Clinical Trials
Unit with particular expertise in running multicentre
RCTs of complex and surgical interventions. The Spon-
sor and CI will ensure, through the TSC, that adequate
systems are in place for monitoring the quality of the
trial (compliance with appropriate governance) and ap-
propriate expedited and routine reports, to a level ap-
propriate to the risk assessment of the trial.
The Trial Co-ordinating Office (TCOD) based in the
Dundee Dental School and Hospital, University of Dun-
dee will provide day-to-day support to the GDPs and
outcome assessors/research nurses. The Trial Office
Teams at TCOD and CHaRT will meet formally ap-
proximately monthly during the course of the trial to en-
sure smooth running and trouble-shooting.
Data collected during the course of the research will
be kept strictly confidential and accessed only by mem-
bers of the trial team. Participants’ details will be stored
on a secure database under the data protection guide-
lines and regular checks and monitoring are in place to
ensure compliance. Data will be archived to a secure
data storage facility. The CTU senior IT manager (in
collaboration with the Chief Investigator) will manage
access rights to the data set. Participants will be allo-
cated an individual specific trial number and their details
will be anonymised on the secure database. We antici-
pate that anonymised trial data may be shared with
other researchers to enable international prospective
meta-analyses.
Manchester University NHS Foundation Trust is the
sponsor for the trial. An independent risk assessment
was carried out by the Sponsor prior to commencement
of the trial and will be reviewed and, if necessary,
updated annually for the duration of follow up. The trial
will be monitored to ensure that the study is being con-
ducted as per protocol, adhering to Research Govern-
ance, and the appropriate regulations. The approach to,
and extent of, monitoring will be specified in a trial
monitoring plan which will be determined by the risk as-
sessment of the study and updated if necessary following
the outcomes of the annual risk assessment review.
The Sponsor will provide indemnity for non-negligent
harm. All dentists and dental care professionals working
on the trial will be registered with the General Dental
Council and have appropriate indemnity arrangements
in place.
Data-handling, record keeping and archiving
Clinical data will be entered into the trial database by
the TCOD together with data from questionnaires com-
pleted at clinic. Questionnaires returned by post to the
trial office will be entered there. Staff in the trial office
will work closely with practices to ensure that the data
are as complete and accurate as possible. Extensive
range and consistency checks will further enhance the
quality of the data. The Sponsor is responsible for ensur-
ing that trial data is archived appropriately. Essential
data shall be retained for a period of at least 15 years fol-
lowing close of trial.
Satellite studies
It is recognised, that the value of the trial may be en-
hanced by smaller ancillary studies of specific aspects.
Plans for these will be discussed in advanced with the
Project Management Group. REC approval will be
sought for any new proposal, if appropriate.
Dissemination
This trial will produce new knowledge which will be
valuable to key stakeholder groups: patients, policy
makers, dental healthcare providers and commercial or-
ganisations both in the UK and internationally. We in-
tend to maintain interest in the trial by publication of
newsletters at intervals for staff and collaborators. Once
the main report has been published, a lay summary of
the findings will be sent in a final Newsletter to all in-
volved in the trial.
We will develop our dissemination strategy as the trial
progresses with our PPI group and engagement with
stakeholder groups. The key stakeholders will be:
1. Policy makers, guideline producers and
commissioners: the four Chief Dental Officers
(CDOs), NICE, SIGN, SDCEP and Public Health
England. At the end of the trial we intend to hold a
workshop for policy makers and produce summary
briefing documents of our findings. The trial team
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will liaise with the editorial team from the
Cochrane Oral Health Group to ensure the timely
update of the relevant Cochrane reviews. We will
engage with international bodies and organisations
such as, WHO, US Centre for Disease Control,
FDI.
2. Clinicians: we will speak at national clinical
conferences, relevant dental specialist society
meetings and produce clinical summary papers in
popular journals read by clinicians.
3. Patients and the public: we will issue press releases
to the popular media and post lay summaries of the
outcomes on our web sites and engage with the
public through social media.
4. Academic community: the principal output will be
a monograph published in accordance with NIHR
guidelines on project outputs [30] in the funder’
journal. In addition, we will aim to publish our
findings in peer-reviewed, high impact,
internationally-leading journals. We will present our
findings at relevant national and international oral
health conferences such as IADR.
5. Industry and commerce: We will provide reports
for major toothpaste manufacturers.
Discussion
The Reflect Trial is an NIHR HTA funded trial that
is being undertaken across England, Northern
Ireland and Scotland. It is a pragmatic, multi-centre,
open-label randomised trial designed to determine
whether or not the substantial and rapidly increasing
costs of prescribing high fluoride concentration
toothpaste benefits patients and represents a wise in-
vestment for the UK National Health Service. The
trial is pragmatic in nature, designed as far as pos-
sible to mirror ‘real life’. This pragmatic approach is
reflected in:
 the population: involved in the trial, high caries risk
older adults, have been identified by national guidance
in England as a key target group for prescribing high
concentration fluoride toothpaste [12]
 the intervention: prescription of high concentration
fluoride toothpaste. 5000 ppm fluoride toothpaste
was chosen, as this higher concentration is likely to
produce the largest effect size (compared to 2800
ppm fluoride toothpaste). The intervention tests the
prescription of the drug by GDPs rather than the
drug being directly provided to participants.
Therefore decisions taken by dentists on the amount
and frequency of prescribing the drug and the
compliance of participants in using the toothpaste
need to be measured and considered in the analysis
and interpretation of results.
 the primary outcome measure: receipt of treatment
as a result of caries was determined by patient and
public involvement as a key concern of patients.
More traditional measures of caries are included as
secondary outcome measures
 the comparator: the intervention will be compared
to ‘usual practice’ as determined by each
participant’s dentist.
Importantly the setting for the trial is primary care den-
tal practices, where the overwhelming majority of patients
receive their dental care. Participants will be recruited in
approximately 60 practices across the three countries,
providing a varied range of practices operating in different
geographical environments and socio-economics circum-
stances and different remuneration systems. This broad
range of practices should ensure the results of this trial
are widely applicable. The evidence base for high concen-
tration fluoride toothpaste is not strong both in terms of
both efficacy and for how well this health technology
works in day-to-day general dental practice. The results of
this pragmatic trial should complement the findings of ef-
ficacy trials to provide high quality evidence on the costs
and benefits of high concentration fluoride toothpaste to
support the decisions of dental practitioners, patients and
policy makers on its use.
The team responsible for the design and delivery of
the trial is multidisciplinary drawn from a strong collab-
oration between the Universities of Aberdeen, Dundee
and Manchester plus colleagues working in the NHS
and local research networks. The trial is a Clinical Trial
of a Investigative Medicinal Product and is overseen by
the trial sponsor Manchester University Foundation
Trust, supported by an independent Trial Steering
Group and Data Management Committee and Patient
and Public Involvement Group. This will ensure that the
trial is conducted to the highest standards. We expect
the Reflect Trial to make an important national and
international contribution to understanding the role that
high concentration fluoride toothpaste can play in the
management of high caries risk in older adults attending
primary dental care.
Trial status
Currently recruiting. Participant recruitment began in May
2018 and is expected to finish recruiting in August 2019.
The first participant was randomised on 03/05/2018.
Current approved protocol: Version 1.2, 16/01/2018.
Additional files
Additional file 1: Appendix 1. Qualitative study protocol. (DOCX 16 kb)
Additional file 2: Appendix 2. Consent form. (DOCX 237 kb)
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Additional file 3: Appendix 3. Scottish sub-protocol. (DOCX 13 kb)
Additional file 4: Appendix 4. SPIRIT checklist. (DOCX 43 kb)
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